OBJECTIVES The dynamic of the reimbursement politics shows a very different pattern in different countries. The REDEL study examined the elapsed time from marketing authorization to the starting date of reimbursement of the original medicines in Central and Eastern European Countries (Austria, Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia). METHODS The basis of comparison were 216 products and their ATC codes selected from the database of the European Medicines Agency which were granted a marketing authorization between 1st January 2007 and 1st July 2013. In the case of these products the research studied the dates, when countries adopted them into their reimbursement system. The adoption was the subject of the study between 1st January 2010 and 1st July 2013. The following three different indicators were calculated in the study: REDEL - the delay between marketing authorization date and reimbursement date; INNREIMB - the number of reimbursed INNs according to a specific country or MAH; SR - Success Rate as the ratio of reimbursed INNs to examined INNs.  RESULTS While an average of 403 days elapsed between the authorization and the starting date of reimbursement in Slovenia (mean of 76 products), the same period was 1295 days in Poland (mean of 21 adoptions). The average is 632 days. The top three in the ranking of REDEL of active substances (ATC 1st level – anatomical main group) were dermatologicals (D), respiratory system (R) and Muscolo-skeletal system (M).  CONCLUSIONS The results show that even threefold differences exist among the studied countries with regards to the reimbursement delay. An average of almost two years elapse until a producer can have the given product adopted into the reimbursement system in a country (the REDEL steadily increasing in the studied period, while the number of reimbursed products decreasing).